Xeris Biopharma (XERS) Stock Price, News & Analysis

Company Overview

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S. Food and Drug Administration for the treatment of severe hypoglycemia in adults and pediatric patients with diabetes. Gvoke is the first and only ready-to-use glucagon rescue product, offering rapid emergency treatment without the time-consuming reconstitution steps required by traditional glucagon kits. In addition to Gvoke, Xeris is advancing a pipeline of liquid-stable therapies, including investigational rescue treatments for seizures and other acute conditions.

Founded in 2008 and headquartered in Chicago, Illinois, Xeris Biopharma operates primarily in the United States while exploring international partnerships to expand the reach of its novel drug-delivery technologies. The company is led by President and Chief Executive Officer Paul Edick, whose leadership has guided Xeris from its early research stages through the commercialization of its first product. As Xeris continues to grow its portfolio, it aims to address unmet needs across a spectrum of endocrine and neurology indications.

Key Stats

• Today's Range: $8.29 to $8.54
• 50-Day Range: $5.89 to $8.94
• 52-Week Range: $4.87 to $10.08
• Volume: 1.18 million shs
• Average Volume: 2.23 million shs
• Market Capitalization: $1.44 billion
• P/E Ratio: 138.67
• Dividend Yield: N/A
• Price Target: $10.80
• Consensus Rating: Moderate Buy

Xeris Biopharma Stock Analysis - MarketRank™

Xeris Biopharma scored higher than 80% of companies evaluated by MarketBeat, and ranked 175th out of 836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Xeris Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Xeris Biopharma has a consensus price target of $10.80, representing about 29.8% upside from its current price of $8.32.

Amount of Analyst Coverage

Xeris Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 175.00%

Earnings Growth

Earnings for Xeris Biopharma are expected to grow by 175.00% in the coming year, from $0.12 to $0.33 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Xeris Biopharma is 138.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 45.80.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xeris Biopharma is 138.67, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.14.

Price to Book Value per Share Ratio

Xeris Biopharma has a P/B Ratio of 104.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.10% of the float of Xeris Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Xeris Biopharma has a short interest ratio ("days to cover") of 4.38.

Change versus previous month

Short interest in Xeris Biopharma has recently decreased by 21.02%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xeris Biopharma does not currently pay a dividend.

Dividend Growth

Xeris Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 1.64

News Sentiment

Xeris Biopharma has a news sentiment score of 1.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Xeris Biopharma this week, compared to 3 articles on an average week.

Search Interest

11 people have searched for XERS on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.

MarketBeat Follows

5 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Xeris Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,846,457.00 in company stock.

Percentage Held by Insiders

4.35% of the stock of Xeris Biopharma is held by insiders.

Percentage Held by Institutions

42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 7/25/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XERS
• CIK: 1867096
• Web: www.xerispharma.com
• Phone: (844) 445-5704
• Fax: N/A
• Employees: 290
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Xeris Biopharma: $10.80
• High Price Target: $18.00
• Low Price Target: $8.00
• Potential Upside/Downside: +29.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.06
• Trailing P/E Ratio: 138.67
• Forward P/E Ratio: 69.33
• P/E Growth: N/A
• Net Income: $550 thousand
• Net Margins: 3.81%
• Pretax Margin: 3.81%
• Return on Equity: 735.00%
• Return on Assets: 3.24%

Debt

• Debt-to-Equity Ratio: 17.00
• Current Ratio: 2.12
• Quick Ratio: 1.50

Sales & Book Value

• Annual Sales: $291.85 million
• Price / Sales: 4.92
• Cash Flow: $0.10 per share
• Price / Cash Flow: 83.06
• Book Value: $0.08 per share
• Price / Book: 104.00

Miscellaneous

• Outstanding Shares: 172,640,000
• Free Float: 165,132,000
• Market Cap: $1.44 billion
• Optionable: Optionable
• Beta: 0.62